自引率: 6.4%
被引量: 5019
通过率: 暂无数据
审稿周期: 4.29
版面费用: 暂无数据
国人发稿量: 16
投稿须知/期刊简介:
Human Immunology will publish research in Immunogenetics, Cellular, Molecular and Clinical Immunology. Section editors for each of these fields have been selected to expedite the review process. The immunogenetics section will present findings on structural polymorphism of HLA genes in healthy and diseased populations, their function, regulation and expression in normal and malignant cells. The molecular immunology section will present research on the structure and function of molecules that play a role in the activation and regulation of the immune system. Cellular immunology will encompass the broad areas of in vitro and in vivo studies of cellular immune responses in transplantation, autoimmunity and infectious diseases. The clinical immunology section will present studies on the immunology of cell, tissue and organ transplantation, autoimmune, allergic and infectious diseases, and anti-tumor responses. Manuscripts will be reviewed and published rapidly. The chief criteria for publication are originality and quality. Pertinent information about immunologic studies in animal systems may also be considered. Topics of general interest form the basis for editorials and special issues. Human Immunology is now available on ContentsDirectTo receive the contents of Human Immunology via e-mail, simply send and e-mail to CDSubs@elsevier.co.uk indicating the name of the journal, your e-mail address, and your mailing address.
期刊描述简介:
Human Immunology will publish research in Immunogenetics, Cellular, Molecular and Clinical Immunology. Section editors for each of these fields have been selected to expedite the review process. The immunogenetics section will present findings on structural polymorphism of HLA genes in healthy and diseased populations, their function, regulation and expression in normal and malignant cells. The molecular immunology section will present research on the structure and function of molecules that play a role in the activation and regulation of the immune system. Cellular immunology will encompass the broad areas of in vitro and in vivo studies of cellular immune responses in transplantation, autoimmunity and infectious diseases. The clinical immunology section will present studies on the immunology of cell, tissue and organ transplantation, autoimmune, allergic and infectious diseases, and anti-tumor responses. Manuscripts will be reviewed and published rapidly. The chief criteria for publication are originality and quality. Pertinent information about immunologic studies in animal systems may also be considered. Topics of general interest form the basis for editorials and special issues.
-
P2RX1-Negative neutrophils promote the immunosuppressive microenvironment in Non-Small cell lung cancer by Upregulating PD-L1 expression.
被引量：- 发表：1970
-
Telomeres and immunodeficiencies.
被引量：- 发表：1970
-
Association of serum level of TGF-B1 and its genetic polymorphisms (C509T and T869C) with Ischemic heart disease in Iraqi population.
被引量：- 发表：1970
-
Enrichment analysis of systemic lupus erythematosus susceptible loci identified by genome-wide association studies.
被引量：- 发表：1970
-
Seroconversion in liver and intestine transplant patients after one, two or three doses of adenoviral vector vaccines against SARS-CoV-2. Single center experience in Argentina.
The capacity of different anti-SARS-CoV-2 vaccines to elicit immune response is not equivalent in the healthy population compared to chronically immunosuppressed patients. Most of the reports available to assess the effects of anti-SARS-CoV-2 vaccines on solid organ transplant recipients (SOTR) were performed using mRNA-based vaccines. This study aims to assess the seroconversion rate in a cohort of liver and liver- intestinal transplant patients after vaccination with the non-replicative vector-based vaccines after transplantation used in our country, Argentina (rAd26-rAd5 (Sputnik V) and ChAdOx11 nCoV-19 (AZD1222) (Astra Zeneca-Oxford). One hundred and three (103) liver and liver-intestinal transplant recipients were enrolled. Patients with previous PCR-confirmed COVID19 were excluded, therefore 77 were finally included for analysis; 75 were liver transplant recipients, 1 was a combined liver-intestine and 1 a multivisceral transplant. All received their first vaccine dose between March and June 2021; 66,2% males, and the mean age was 56,3 years. All patients have a post-transplant follow up longer than 1 year (mean 6.6 years, median 5 years, range 1-23 years). Immune response after first, second and third doses were determined using three different spike (S)-S commercial ELISA kits and an in-house made anti nucleocapsid-protein (N) ELISA. Following the three doses, 57.1 % (44/77) of the patients seroconverted, while 33/77 (42.9 %) did not present anti-SARS-CoV-2 antibodies. The seroconversion rate was different for each dose. We found that 5/27 (18.5 %) of transplant patients seroconverted after a single dose; 18/29 pts (62.0 %) had anti-SARS-Cov-2 antibodies after the second doses; and 18/21 pts (85.7 %) reached the seroconversion after the third doses. The proportion of seroconversion was significantly increased in the second doses regardless the response observed after the first doses (p = 0.012, Fisher's exact test), particularly when two doses of ChAdOx11 vaccine was administrated (p = 0.040, Chi-square). However, the comparisons of seroconversion rate between Sputnik V and ChAdOx11 vaccines showed no differences after the different vaccination doses. No significant statistical difference in patient́s gender, age, comorbidities, type of vaccine, post-transplant, or maintenance immunosuppressive therapy was found between responders and non-responders. Despite having a lower seroconversion rate compared to the general population, viral-vector vaccines benefit SOTR patients increasing the seroconversion rate using at least two doses of vaccine. These results support the concept of developing tailor-made vaccination guidelines for this specific population. This analysis provides further support to safety and efficacy of viral-vector vaccines in liver and liver-intestine transplant patients.
被引量：- 发表：1970
